S111. Randomized, Double-Blind Study of Flexibly-Dosed Intranasal Esketamine Plus Oral Antidepressant Vs. Active Control in Treatment-Resistant Depression

Vanina Popova; Ella Daly; Madhukar H. Trivedi; Kimberly Cooper; R. Lane; Pilar Lim; Christine Mazzucco; David Hough; Michael E. Thase; Richard C. Shelton; Patricio Molero; Eduard Vieta; Malek Bajbouj; Husseini K. Manji; Wayne C. Drevets; Jaskaran Singh

doi:10.1016/j.biopsych.2018.02.1002

Back

Shared by

Eduard Vieta

S111. Randomized, Double-Blind Study of Flexibly-Dosed Intranasal Esketamine Plus Oral Antidepressant Vs. Active Control in Treatment-Resistant Depression

Article 2018 en

Authors

VP
Vanina Popova
ED
Ella Daly
MT
Madhukar H. Trivedi

Related publications

Article2019

Randomized, double-blind study of flexibly-dosed intranasal esketamine plus oral antidepressant vs. active control in treatment-resistant depression

Vanina Popova, Ella Daly, Madhukar H. Trivedi, Kevin Cooper, R. Lane, Pilar Lim, Christine Mazzucco, David Hough, Michael E. Thase, Richard C. Shelton, Patricio Molero, Eduard Vieta, Malek Bajbouj, Husseini K. Manji, Wayne C. Drevets, Jaskaran Singh

Article1995

Oral brivudin vs. intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: A randomized double‐blind trial

Peter Wutzler, De Clercq Erik, K Wutke, Inge Färber

Article2001

Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study

M. Bhushan, A. David Burden, Kathleen McElhone, R. L. James, Frédéric Vanhoutte, Christopher Em Griffiths

Article2010

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study

Giancarlo Comi, Oded Abramsky, Txomin Arbizu, Ralf Gold, Eva Havrdová, Sámuel Komoly, Krzysztof Selmaj, Basil Sharrack, Massimo Filippi

Article2024

Treatment patterns of esketamine nasal spray amongst patients with treatment resistant depression in a phase IIIb study: results from ESCAPE-TRD

A. Reif, Eduard Vieta, Peter Falkai, Bernhard T. Baune, E. Buntinx, Philip Gorwood, Y. Godinov, C. von Holt, Jozefien Buyze, Tetsuro Ito

S111. Randomized, Double-Blind Study of Flexibly-Dosed Intranasal Esketamine Plus Oral Antidepressant Vs. Active Control in Treatment-Resistant Depression

Discussion(0)

Related publications

Randomized, double-blind study of flexibly-dosed intranasal esketamine plus oral antidepressant vs. active control in treatment-resistant depression

Oral brivudin vs. intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: A randomized double‐blind trial

Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study

Treatment patterns of esketamine nasal spray amongst patients with treatment resistant depression in a phase IIIb study: results from ESCAPE-TRD